The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Topic engagement Tell us about the 5 key areas for quality improvement which you consider as having the greatest potential to improve the quality of care in this area. Closing date for comments: ...

NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the ...

Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...

Sparsentan (Filspari, Vifor) is indicated for 'the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any ...

When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has immunoglobulin A ...

primary IgA nephropathy affects approximately 18,000 people in England 47.71% of these people have chronic kidney disease (CKD) stages 1-3 based on company internal market research 47.18% of people ...

Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiu0002PD-L1 treatment and platinum-based chemotherapy [TSID12211] ...